Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 38Recruiting 31Completed 15Terminated 11Withdrawn 8Active not recruiting 8Not yet recruiting 3Suspended 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Adenocarcinoma 1Cholangiocarcinoma 1

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 5Nivolumab 4Capecitabine 4Vincristine 3Radiosurgery 3Paclitaxel 3Irinotecan 3Fluorouracil 3Everolimus 3Docetaxel 3Dexamethasone 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3trifluridine tipiracil drug combination 2spartalizumab 2pembrolizumab 2lenvatinib 2daratumumab 2Taxes 2Radiation 2Prednisone 2Pemetrexed 2Oxaliplatin 2Mitoxantrone 2Leucovorin 2Injections 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Suspended × spartalizumab × Clear all
NCT06728657 2025-06-18

TORCH-G

Fudan University

Phase 2 Suspended
68 enrolled
Gastrointestinal

Stomach Adenocarcinoma

NCT03779100 2019-01-28

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Sun Yat-sen University

Phase 2 Suspended
25 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡